Clinical Evaluation of Ksheervidari and Bhumyamlaki in Essential Hypertension

Comparative Clinical Evaluation of Ksheervidari and Bhumyamlaki in the management of Shonitpradoshaj Vikara w.s.r. Essential Hypertension -A Randomized Prospective Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/02/031555

Enrollment

100

Registered

2021-02-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Ksheervidari (Ipomoea digitata Linn., Ipomoea paniculata (Linn.) R.Br.): Group A: Trial drug - Aqueous extract of Ksheervidari (Ipomoea digitata) Dose - 500mg Dosage Form -Tablet Anupa

Eligibility

Inclusion criteria

Inclusion criteria: i. Subjects willing to participate in this clinical trial. ii. Patients of either sex in the age group 18-70years. iii. Patients with Stage I Hypertension as per JNC-7 classificationi.e. Systolic blood pressure (SBP) in the range of 140-159 mm of Hg and/or Diastolic blood pressure (DBP) ranging between 90-99 mm of Hg will be included in the study.

Exclusion criteria

Exclusion criteria: i. Patient not willing to sign the consent form. ii. Patients below 18 years and above 70 years of age. iii. Patientswith Stage II Hypertension. iv. Patients with Secondary Hypertension. v. Patients taking any antihypertensive medication or who have taken any antihypertensive medication within previous one month. vi. Patients having any serious illness like Coronary Artery Disease,Cerebrovascular disease, Insulin dependent Diabetes mellitus,Malignancy, etc. vii. Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter or other significant arrhythmia. viii. Patients with any Endocrinal disorders, Renaldisorder or Hepatic disorders. ix. Patients taking drugs like corticosteroids, oral contraceptives, NSAIDs etc. which may influence the outcome of the study. x. Patients who show any hypersensitivity towards the trial drugs. xi. Pregnant and Lactating mothers.

Design outcomes

Primary

Measure	Time frame
Reduction in Systolic and diastolic blood pressureTimepoint: Day 0, 15, 30, 45, 60	—

Secondary

Measure	Time frame
Improvement in subjective symptoms of Raktapradoshaj vikara ï?? Akshiraga(Redness in eyes) ï?? Raktapitta(Nasal Bleeding) ï?? Santapa(Burning sensation) ï?? Daurbalya(Weakness) ï?? Shirashoola(Headache) ï?? Tikta-amlodgara(Sour& bitter eructations) ï?? Klama(Easy fatigability) ï?? Krodhaprachurta(Irritability) ï?? Budhisamoha(Impaired perception) ï?? Tandra(Drowsiness) ï?? Nidratiyoga(Excessive Sleep) ï?? Tamadarshan(Blackouts) ï?? Mada(Dizziness) ï?? Kampa(Palpitations) Timepoint: 60 days	—

Measure

Time frame

Improvement in subjective symptoms of Raktapradoshaj vikara ï?? Akshiraga(Redness in eyes) ï?? Raktapitta(Nasal Bleeding) ï?? Santapa(Burning sensation) ï?? Daurbalya(Weakness) ï?? Shirashoola(Headache) ï?? Tikta-amlodgara(Sour& bitter eructations) ï?? Klama(Easy fatigability) ï?? Krodhaprachurta(Irritability) ï?? Budhisamoha(Impaired perception) ï?? Tandra(Drowsiness) ï?? Nidratiyoga(Excessive Sleep) ï?? Tamadarshan(Blackouts) ï?? Mada(Dizziness) ï?? Kampa(Palpitations) Timepoint: 60 days

—

Countries

India

Contacts

Public ContactAbhishek Upadhyay

National Institute of Ayurveda Jaipur

joshirk1964@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026